The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
A Study of Nivolumab in Selected Uterine Cancer Patients
Clinicaltrials.gov identifier:
NCT03241745
Study Contact Information:
Principal Investigator:
Claire Friedman, MD
by phone: 646-888-4247 or by email
A Study of Nivolumab in Selected Uterine Cancer Patients
About the Study
The purpose of this study is to test the effectiveness, safety, and tolerability of Nivolumab on patients with or recurrent uterine cancer.
Nivolumab is a type of known as an immune checkpoint inhibitor. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells. NOTE: This study is no longer enrolling.
NOTE: This study is no longer enrolling.
NOTE: This study is no longer enrolling.